TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 172 filers reported holding TRAVERE THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.29 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,576,000 | +156.5% | 400,000 | +340.8% | 0.12% | +197.5% |
| Q2 2023 | $1,393,889 | -31.7% | 90,748 | 0.0% | 0.04% | -33.3% |
| Q1 2023 | $2,040,923 | +6.9% | 90,748 | 0.0% | 0.06% | +11.1% |
| Q4 2022 | $1,908,430 | -14.6% | 90,748 | 0.0% | 0.05% | -16.9% |
| Q3 2022 | $2,236,000 | -83.8% | 90,748 | -84.1% | 0.06% | -85.0% |
| Q2 2022 | $13,813,000 | -71.0% | 570,084 | -69.1% | 0.43% | -54.6% |
| Q1 2022 | $47,560,000 | -58.5% | 1,845,555 | -50.0% | 0.95% | +7.8% |
| Q4 2021 | $114,572,000 | +140.4% | 3,691,110 | +87.8% | 0.88% | +27.7% |
| Q3 2021 | $47,665,000 | -11.5% | 1,965,555 | -46.7% | 0.69% | +97.7% |
| Q2 2021 | $53,854,000 | -34.6% | 3,691,110 | +11.9% | 0.35% | -66.4% |
| Q1 2021 | $82,362,000 | -13.5% | 3,298,419 | -5.6% | 1.04% | +2.0% |
| Q4 2020 | $95,218,000 | – | 3,493,607 | – | 1.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 1,028,875 | $25,351,000 | 8.34% |
| GREAT POINT PARTNERS LLC | 966,108 | $23,805,000 | 5.73% |
| Deep Track Capital, LP | 4,000,000 | $98,560,000 | 4.51% |
| RA Capital Management | 4,922,941 | $121,301,000 | 2.59% |
| ARMISTICE CAPITAL, LLC | 5,836,000 | $143,799,000 | 2.49% |
| Kynam Capital Management, LP | 416,729 | $10,268,000 | 2.16% |
| MPM BioImpact LLC | 276,460 | $6,812,000 | 1.61% |
| HighVista Strategies LLC | 110,698 | $2,728,000 | 1.56% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 186,019 | $4,582,000 | 1.47% |
| SECTORAL ASSET MANAGEMENT INC | 249,700 | $6,153,000 | 1.21% |